An unsteady geopolitical situation in eastern Europe, worldwide inflation and the politicization of drug pricing in the US all made their mark on 2023. Making predictions about the biopharma world is always a tricky endeavor, but looking ahead into 2024 reveals an uptick in deal-making and perhaps the return of larger scale M&A, as big pharma feels the pressure to fill pipeline gaps at a faster rate. The unprecedented demand for new treatments in obesity has meant a couple of companies have fuller pockets and, in turn, more cash to put to work.
The industry is moving closer to a large and extended patent cliff, a period of time from 2025 to the...
